Currently, there are ongoing clinical trials which investigate the <i>MET</i> amplification as a therapeutic target in patients with <i>EGFR</i> mutant NSCLC and acquired resistance to osimertinib, which imply that the <i>MET</i> amplification also had a therapeutic significance. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.